Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$ABOT ABT Reports Success in Beta Testing of its AutoClaim App
Source: InvestorsHub NewsWire
ABT Reports Success in Beta Testing of its AutoClaim App
Pasadena, CA -- February 11, 2016 -- InvestorsHub NewsWire -- ABT Holdings (OTC Pink: “ABOT,” or the “Company”) today announced that it has received positive feedback on beta testing of the “AutoClaim” App Version 4.1 from beta-testers, which included, among several things, benefits and features of the app, desirability to download the app, and end-user experience on the usage of app under normal and stress (during simulated accident scenario) conditions.
The Company is a pioneer in real time Mobile Claims Documentation and Management System and expects to launch the App nationwide by the end of the first quarter of fiscal 2016. The Company is continuously receiving pre-launch awareness as AutoClaim.com is among the premium insurance domain names that generates natural online traffic.
Commenting on the Company’s direction for the launch of AutoClaim App for personal use, Shahan Ohanessian said, “Current test results are clearly showing that the App is delivering the promised user experience with respect to benefits and functionalities. In the next coming weeks, our AutoClaim marketing team will be launching several social media and branding campaigns for a major launch, while the operations team is establishing a solid customer and tech support for our end-users.”
For more details on ABT Holdings, click here.
For more details on AutoClaim App, click here.
For more details on Scoobeez, click here.
For more Company information, click here.
About Scoobeez, subsidiary of ABT Holdings, Inc.
Based in Los Angeles, California, Scoobeez is a “Real Time Delivery” and “Same Day” door to door delivery service company that facilitates same day deliveries for enterprise clients. Scoobeez’s value proposition includes utilization of technologies, exceptional customer experience, and logistic creativity to deliver its clients’ products to their customers within the shortest possible time-frame. For more information, please visit Company’s website by clicking here. You may connect and follow Scoobeez on Facebook, Twitter and Instagram.
About the Company
ABT Holdings, Inc. is a diversified holding company engaged in acquiring, developing and growing various businesses that provide strategic advantages, generate attractive returns and significant free cash flow in order to maximize value of our shareholders.
Safe Harbor / Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on the Company’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our possible need for financing; uncertainties of technological changes; and dependence upon third parties. The Company does not undertake an obligation to update or revise any forward-looking statement. All of the Company’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date hereof.
Company Contact:
Imran Firoz, CFO
ABT Holdings, Inc.
OTC PINK: ABOT
225 S Lake Avenue | Suite 300 | Pasadena | CA 91101
T: +1 818.302.0100
E: ir@abtholdings.com
$ABOT ABT Reports Success in Beta Testing of its AutoClaim App
Source: InvestorsHub NewsWire
ABT Reports Success in Beta Testing of its AutoClaim App
Pasadena, CA -- February 11, 2016 -- InvestorsHub NewsWire -- ABT Holdings (OTC Pink: “ABOT,” or the “Company”) today announced that it has received positive feedback on beta testing of the “AutoClaim” App Version 4.1 from beta-testers, which included, among several things, benefits and features of the app, desirability to download the app, and end-user experience on the usage of app under normal and stress (during simulated accident scenario) conditions.
The Company is a pioneer in real time Mobile Claims Documentation and Management System and expects to launch the App nationwide by the end of the first quarter of fiscal 2016. The Company is continuously receiving pre-launch awareness as AutoClaim.com is among the premium insurance domain names that generates natural online traffic.
Commenting on the Company’s direction for the launch of AutoClaim App for personal use, Shahan Ohanessian said, “Current test results are clearly showing that the App is delivering the promised user experience with respect to benefits and functionalities. In the next coming weeks, our AutoClaim marketing team will be launching several social media and branding campaigns for a major launch, while the operations team is establishing a solid customer and tech support for our end-users.”
For more details on ABT Holdings, click here.
For more details on AutoClaim App, click here.
For more details on Scoobeez, click here.
For more Company information, click here.
About Scoobeez, subsidiary of ABT Holdings, Inc.
Based in Los Angeles, California, Scoobeez is a “Real Time Delivery” and “Same Day” door to door delivery service company that facilitates same day deliveries for enterprise clients. Scoobeez’s value proposition includes utilization of technologies, exceptional customer experience, and logistic creativity to deliver its clients’ products to their customers within the shortest possible time-frame. For more information, please visit Company’s website by clicking here. You may connect and follow Scoobeez on Facebook, Twitter and Instagram.
About the Company
ABT Holdings, Inc. is a diversified holding company engaged in acquiring, developing and growing various businesses that provide strategic advantages, generate attractive returns and significant free cash flow in order to maximize value of our shareholders.
Safe Harbor / Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on the Company’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our possible need for financing; uncertainties of technological changes; and dependence upon third parties. The Company does not undertake an obligation to update or revise any forward-looking statement. All of the Company’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date hereof.
Company Contact:
Imran Firoz, CFO
ABT Holdings, Inc.
OTC PINK: ABOT
225 S Lake Avenue | Suite 300 | Pasadena | CA 91101
T: +1 818.302.0100
E: ir@abtholdings.com
$TSGL The Staffing Group to Acquire North Dakota Industrial Staffing Firm
Source: InvestorsHub NewsWire
The Staffing Group to Acquire North Dakota Industrial Staffing Firm
Company Plans Industry Roll-up
Atlanta, GA, United States, via NZINET CORP., 02/11/2016 - - The Staffing Group, Ltd. (OTC PINK: TSGL) (the "Company"), today announced it plans to acquire a North Dakota industrial staffing firm.
With three locations operating in North Dakota, the acquisition target provides skilled personnel to various industries including trucking, manufacturing, construction, and the oil and gas industry in the Bakken Shale Region.
The proposed transaction is expected to add as much as $6 million in revenue to the Company in 2016 and in excess of $8.5 million in 2017. Definitive terms are being finalized and the Company expects to close on the acquisition upon a successful completion of its equity raise. On February 4, 2016, the Company filed a Form D with the U.S. Securities and Exchange Commission, stating its intention to raise $5 million in a non-brokered private placement.
After divesting underperforming assets and a swift clean-up of its balance sheet at the end of 2015, the Company is now focused on executing an aggressive buy-and-build strategy through the acquisition and integration of small to medium sized staffing businesses with focus on the light industrial, engineering, manufacturing and construction staffing space. The Company believes the light industrial staffing segment is ripe for consolidation and will seek accretive acquisitions that will drive annual revenues to $75 million within the next 36 months.
Safe Harbor Statement
This release contains statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of The Staffing Group, Ltd.., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy. The words "may", "would", "will", "expect", "estimate", "can", "believe", "potential", and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond The Staffing Group, Ltd.'s ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. More information about the potential factors that could affect the business and financial results is and will be included in The Staffing Group, Ltd.'s filings with the U.S. Securities and Exchange Commission.
Contact Information
Contact Information
The Staffing Group, Ltd.
Kim Thompson
678-881-0834
kthompson@staffinggroupltd.com
$TSGL The Staffing Group to Acquire North Dakota Industrial Staffing Firm
Source: InvestorsHub NewsWire
The Staffing Group to Acquire North Dakota Industrial Staffing Firm
Company Plans Industry Roll-up
Atlanta, GA, United States, via NZINET CORP., 02/11/2016 - - The Staffing Group, Ltd. (OTC PINK: TSGL) (the "Company"), today announced it plans to acquire a North Dakota industrial staffing firm.
With three locations operating in North Dakota, the acquisition target provides skilled personnel to various industries including trucking, manufacturing, construction, and the oil and gas industry in the Bakken Shale Region.
The proposed transaction is expected to add as much as $6 million in revenue to the Company in 2016 and in excess of $8.5 million in 2017. Definitive terms are being finalized and the Company expects to close on the acquisition upon a successful completion of its equity raise. On February 4, 2016, the Company filed a Form D with the U.S. Securities and Exchange Commission, stating its intention to raise $5 million in a non-brokered private placement.
After divesting underperforming assets and a swift clean-up of its balance sheet at the end of 2015, the Company is now focused on executing an aggressive buy-and-build strategy through the acquisition and integration of small to medium sized staffing businesses with focus on the light industrial, engineering, manufacturing and construction staffing space. The Company believes the light industrial staffing segment is ripe for consolidation and will seek accretive acquisitions that will drive annual revenues to $75 million within the next 36 months.
Safe Harbor Statement
This release contains statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of The Staffing Group, Ltd.., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy. The words "may", "would", "will", "expect", "estimate", "can", "believe", "potential", and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond The Staffing Group, Ltd.'s ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. More information about the potential factors that could affect the business and financial results is and will be included in The Staffing Group, Ltd.'s filings with the U.S. Securities and Exchange Commission.
Contact Information
Contact Information
The Staffing Group, Ltd.
Kim Thompson
678-881-0834
kthompson@staffinggroupltd.com
$JNSH JNS Holdings Increases its Authorized Shares of Common Stock
Source: InvestorsHub NewsWire
JNS Holdings Increases its Authorized Shares of Common Stock
Wheeling, IL -- February 11, 2016 -- InvestorsHub NewsWire -- JNS Holdings (OTC: JNSH) today announced it has approved an amendment to its Certificate of Incorporation to increase the number of authorized shares of JNS Holdings common stock from 200,000,000 to 300,000,000. The company stated that the increase in authorized shares is intended to restore our flexibility to position JNS Holdings for future growth.
JNS Holdings has and always will operate in an extremely conservative manor and believes that it is prudent to increase the authorized number of shares of common stock to meet business needs, such as upgrading our owned and operated EV charging network and or any equity offering, promptly as they arise.
Brian Howe President & CEO stated, The company anticipates that the increase of our authorized common shares will make its stock more accessible to investors, enhance liquidity for shareholders, and further enhance growth.
About JNS Holdings Corporation:
JNS Holdings focuses on building solid growth for our investors and shareholders through expansion of our core businesses and subsidiaries, see (www.jnsholdings.com) while seeking additional strategic opportunities. JNS Power & Evolve USA Charging Corporation is the Chicago (IL) based subsidiaries of JNS Holdings specializing in EV infrastructure solutions. JNS is committed in creating a useful and well maintained network for EV charging. The corporate headquarters is located in Wheeling, Illinois. Connect with JNSH on Facebook or Twitter.
This press release does not constitute an offer of any securities for sale. This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ. All forward-looking statements in this press release are based on information available to the company as of the date hereof, and the company undertakes no
obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.
Contacts
JNS Holdings Corporation
Brian Howe CEO
www.jnsholdings.com
info@jnsholdings.com
(847) 520-2899
$JNSH JNS Holdings Increases its Authorized Shares of Common Stock
Source: InvestorsHub NewsWire
JNS Holdings Increases its Authorized Shares of Common Stock
Wheeling, IL -- February 11, 2016 -- InvestorsHub NewsWire -- JNS Holdings (OTC: JNSH) today announced it has approved an amendment to its Certificate of Incorporation to increase the number of authorized shares of JNS Holdings common stock from 200,000,000 to 300,000,000. The company stated that the increase in authorized shares is intended to restore our flexibility to position JNS Holdings for future growth.
JNS Holdings has and always will operate in an extremely conservative manor and believes that it is prudent to increase the authorized number of shares of common stock to meet business needs, such as upgrading our owned and operated EV charging network and or any equity offering, promptly as they arise.
Brian Howe President & CEO stated, The company anticipates that the increase of our authorized common shares will make its stock more accessible to investors, enhance liquidity for shareholders, and further enhance growth.
About JNS Holdings Corporation:
JNS Holdings focuses on building solid growth for our investors and shareholders through expansion of our core businesses and subsidiaries, see (www.jnsholdings.com) while seeking additional strategic opportunities. JNS Power & Evolve USA Charging Corporation is the Chicago (IL) based subsidiaries of JNS Holdings specializing in EV infrastructure solutions. JNS is committed in creating a useful and well maintained network for EV charging. The corporate headquarters is located in Wheeling, Illinois. Connect with JNSH on Facebook or Twitter.
This press release does not constitute an offer of any securities for sale. This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ. All forward-looking statements in this press release are based on information available to the company as of the date hereof, and the company undertakes no
obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.
Contacts
JNS Holdings Corporation
Brian Howe CEO
www.jnsholdings.com
info@jnsholdings.com
(847) 520-2899
$PSID Biotech & Medical Device Companies Make Significant Sales Growth Progress with Advanced Healthcare Products Fueling New
Source: InvestorsHub NewsWire
Biotech & Medical Device Companies Make Significant Sales Growth Progress with Advanced Healthcare Products Fueling New Distributor Opportunities
Coral Springs, FL (February 11, 2016) -- Industry experts forecast continued growth for the biotech - healthcare products industry, especially for medical device market projected to reach new levels as innovative applications & technologies move sector forward. Healthcare services and medical device product companies with recent developments of importance in the markets are PositiveID Corporation (OTC: PSID), Electromed, Inc. (NYSE: ELMD), DexCom, Inc. (NASDAQ: DXCM), Boston Scientific Corporation (NYSE: BSX) and ResMed Inc. (NYSE: RMD)
PositiveID Corporation (OTCQB: PSID), a life sciences company focused on detection and diagnostics, announced today that its Thermomedics subsidiary, which markets the Caregiver FDA-cleared non-contact thermometer, made significant progress on its growth plan in January 2016, including entering into agreements with five new healthcare products distributors, increasing sequential monthly sales growth, and establishing several near-term pipeline opportunities. Thermomedics Caregiver thermometer is targeting the fastest growing segment of the global temperature monitoring device market, estimated at $1 billion by 2020. Caregiver is a clinical grade, infrared thermometer for measurement of forehead temperature in adults, children, and infants, without contact. It delivers an oral-equivalent temperature directly from the forehead in 1-2 seconds. Since there is no skin contact and Caregiver does not require probe cover supplies, it reduces the risk of cross-contamination, which is an increasing concern, and saves healthcare facilities the cost of covers (as much as $0.05 to $0.10 per temperature), storage space, and waste disposal costs.
Read the full PositiveID (PSID) Press Release at http://www.financialnewsmedia.com/profiles/psid.html
It is estimated that Caregiver can offer savings of $250 or more per year per device in probe cover supplies alone. Other methods of clinical thermometry, which include predictive oral/rectal/axillary electronic, infrared tympanic, temporal artery contact scanner, etc., may require expensive protective probe covers, intensive technique concentration, which make them prone to mistaken placement or dwell time, and many have the potential to need replacement metal probes, cords, or other parts. January 2016 was the first full month of Thermomedics operations under PositiveIDs management control, stated William J. Caragol, Chairman and CEO of PositiveID. We already see that by better capitalizing the business, entering into new distribution agreements, managing inventory, and planning for the future, we can generate immediate results in this business operationally and financially.
In other Healthcare Services & Products news and developments: Electromed, Inc. (NYSE: ELMD) this week announced financial results for the three- and six-month periods ended December 31, 2015. Net revenues for the second quarter of fiscal 2016 were $6.26 million, a 28.3% or $1.38 million increase, compared to the second quarter of fiscal 2015. Growth in total net revenues was attributable to strong results in the home care market in which revenue increased by 21.5%, or $0.97 million, compared to the same period of fiscal 2015. Home care sales, which accounted for nearly 88% of revenues, increased due to a higher number of approvals, a higher conversion rate of referrals to approvals, and a higher average selling price from third party payers, such as insurance companies, Medicare and Medicaid, for the Companys SmartVest products.
DexCom, Inc. (NASDAQ: DXCM), developing and marketing continuous glucose monitoring systems for ambulatory use by patients and by healthcare providers in the hospital, this week announced that management will present an update on DexCom at the following upcoming investor conference: Steven Pacelli, Executive Vice President, Strategy and Corporate Development, will present an update on the company at the Leerink Partners 5th Annual Global Healthcare Conference in New York City, New York on Thursday, February 11, 2016 at 3:05pm (EST). The presentation, which will occur live at the Waldorf Astoria Hotel, will be concurrently webcast. The link to the webcast will be available on the DexCom website at www.dexcom.com by navigating to Our Company, then Investor Relations, and finally Events and Webcasts and will be archived there for future reference.
Boston Scientific Corporation (NYSE: BSX) announced the Centers for Medicare and Medicaid Services (CMS) will cover percutaneous left atrial appendage closure (LAAC) therapy under specific criteria, as outlined in the agency's final National Coverage Determination (NCD). This decision, effective immediately, provides consistent and uniform access to the WATCHMAN LAAC Device as a non-pharmacological treatment option for stroke risk reduction for appropriate Medicare beneficiaries. "We are very pleased CMS has established national coverage for this life-changing therapy for Medicare beneficiaries who have a reason to seek an alternative to long-term anticoagulation," said Mike Mahoney, president and chief executive officer, Boston Scientific. "The final decision reflects more than a decade of robust clinical evidence and will facilitate additional data collection via a prospective national registry."
ResMed (NYSE: RMD), the world's leading innovator in sleep-disordered breathing and respiratory care, today announced it completed the acquisition of Inova Labs Inc., a privately-held medical device company that develops and commercializes innovative oxygen therapy products. "We are excited to complete this acquisition, which expands our offerings and solutions to address a global COPD epidemic impacting tens of millions of people," said Mick Farrell, CEO of ResMed. "This acquisition is an important step to reach our goal of improving 20 million lives by 2020.
FinancialNewsMedia.com is leading provider of third party publishing & news dissemination services. If you would like more information regarding our news coverage solutions, please visit financialnewsmedia.com for more details. Get an edge on the market with our Premium News Alerts that are FREE for a limited time at financialnewsmedia.com. Follow us on Facebook: facebook.com/financialnewsmedia and Twitter: twitter.com/FNMgroup.
DISCLAIMER: FN Media Group LLC (FNMG) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNMG is NOT affiliated in any manner with any company mentioned herein. FNMG and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNMG has been compensated three thousand eight hundred dollars for news coverage of the current press release issued by PositiveID Corporation by the company. FNMG HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.
Contact Information:
Company: FN Media Group, LLC
Contact email: editor@financialnewsmedia.com
U.S. Phone: (954)345-0611
URL: www.financialnewsmedia.com
Source: FN Media Group
$PSID Biotech & Medical Device Companies Make Significant Sales Growth Progress with Advanced Healthcare Products Fueling New
Source: InvestorsHub NewsWire
Biotech & Medical Device Companies Make Significant Sales Growth Progress with Advanced Healthcare Products Fueling New Distributor Opportunities
Coral Springs, FL (February 11, 2016) -- Industry experts forecast continued growth for the biotech - healthcare products industry, especially for medical device market projected to reach new levels as innovative applications & technologies move sector forward. Healthcare services and medical device product companies with recent developments of importance in the markets are PositiveID Corporation (OTC: PSID), Electromed, Inc. (NYSE: ELMD), DexCom, Inc. (NASDAQ: DXCM), Boston Scientific Corporation (NYSE: BSX) and ResMed Inc. (NYSE: RMD)
PositiveID Corporation (OTCQB: PSID), a life sciences company focused on detection and diagnostics, announced today that its Thermomedics subsidiary, which markets the Caregiver FDA-cleared non-contact thermometer, made significant progress on its growth plan in January 2016, including entering into agreements with five new healthcare products distributors, increasing sequential monthly sales growth, and establishing several near-term pipeline opportunities. Thermomedics Caregiver thermometer is targeting the fastest growing segment of the global temperature monitoring device market, estimated at $1 billion by 2020. Caregiver is a clinical grade, infrared thermometer for measurement of forehead temperature in adults, children, and infants, without contact. It delivers an oral-equivalent temperature directly from the forehead in 1-2 seconds. Since there is no skin contact and Caregiver does not require probe cover supplies, it reduces the risk of cross-contamination, which is an increasing concern, and saves healthcare facilities the cost of covers (as much as $0.05 to $0.10 per temperature), storage space, and waste disposal costs.
Read the full PositiveID (PSID) Press Release at http://www.financialnewsmedia.com/profiles/psid.html
It is estimated that Caregiver can offer savings of $250 or more per year per device in probe cover supplies alone. Other methods of clinical thermometry, which include predictive oral/rectal/axillary electronic, infrared tympanic, temporal artery contact scanner, etc., may require expensive protective probe covers, intensive technique concentration, which make them prone to mistaken placement or dwell time, and many have the potential to need replacement metal probes, cords, or other parts. January 2016 was the first full month of Thermomedics operations under PositiveIDs management control, stated William J. Caragol, Chairman and CEO of PositiveID. We already see that by better capitalizing the business, entering into new distribution agreements, managing inventory, and planning for the future, we can generate immediate results in this business operationally and financially.
In other Healthcare Services & Products news and developments: Electromed, Inc. (NYSE: ELMD) this week announced financial results for the three- and six-month periods ended December 31, 2015. Net revenues for the second quarter of fiscal 2016 were $6.26 million, a 28.3% or $1.38 million increase, compared to the second quarter of fiscal 2015. Growth in total net revenues was attributable to strong results in the home care market in which revenue increased by 21.5%, or $0.97 million, compared to the same period of fiscal 2015. Home care sales, which accounted for nearly 88% of revenues, increased due to a higher number of approvals, a higher conversion rate of referrals to approvals, and a higher average selling price from third party payers, such as insurance companies, Medicare and Medicaid, for the Companys SmartVest products.
DexCom, Inc. (NASDAQ: DXCM), developing and marketing continuous glucose monitoring systems for ambulatory use by patients and by healthcare providers in the hospital, this week announced that management will present an update on DexCom at the following upcoming investor conference: Steven Pacelli, Executive Vice President, Strategy and Corporate Development, will present an update on the company at the Leerink Partners 5th Annual Global Healthcare Conference in New York City, New York on Thursday, February 11, 2016 at 3:05pm (EST). The presentation, which will occur live at the Waldorf Astoria Hotel, will be concurrently webcast. The link to the webcast will be available on the DexCom website at www.dexcom.com by navigating to Our Company, then Investor Relations, and finally Events and Webcasts and will be archived there for future reference.
Boston Scientific Corporation (NYSE: BSX) announced the Centers for Medicare and Medicaid Services (CMS) will cover percutaneous left atrial appendage closure (LAAC) therapy under specific criteria, as outlined in the agency's final National Coverage Determination (NCD). This decision, effective immediately, provides consistent and uniform access to the WATCHMAN LAAC Device as a non-pharmacological treatment option for stroke risk reduction for appropriate Medicare beneficiaries. "We are very pleased CMS has established national coverage for this life-changing therapy for Medicare beneficiaries who have a reason to seek an alternative to long-term anticoagulation," said Mike Mahoney, president and chief executive officer, Boston Scientific. "The final decision reflects more than a decade of robust clinical evidence and will facilitate additional data collection via a prospective national registry."
ResMed (NYSE: RMD), the world's leading innovator in sleep-disordered breathing and respiratory care, today announced it completed the acquisition of Inova Labs Inc., a privately-held medical device company that develops and commercializes innovative oxygen therapy products. "We are excited to complete this acquisition, which expands our offerings and solutions to address a global COPD epidemic impacting tens of millions of people," said Mick Farrell, CEO of ResMed. "This acquisition is an important step to reach our goal of improving 20 million lives by 2020.
FinancialNewsMedia.com is leading provider of third party publishing & news dissemination services. If you would like more information regarding our news coverage solutions, please visit financialnewsmedia.com for more details. Get an edge on the market with our Premium News Alerts that are FREE for a limited time at financialnewsmedia.com. Follow us on Facebook: facebook.com/financialnewsmedia and Twitter: twitter.com/FNMgroup.
DISCLAIMER: FN Media Group LLC (FNMG) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNMG is NOT affiliated in any manner with any company mentioned herein. FNMG and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNMG has been compensated three thousand eight hundred dollars for news coverage of the current press release issued by PositiveID Corporation by the company. FNMG HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.
Contact Information:
Company: FN Media Group, LLC
Contact email: editor@financialnewsmedia.com
U.S. Phone: (954)345-0611
URL: www.financialnewsmedia.com
Source: FN Media Group
$VEND Fresh Healthy Vending Adds Reis and Irvy's Frozen Yogurt Robot to Franchise Portfolio
Source: InvestorsHub NewsWire
SOURCE: Fresh Healthy Vending International, Inc.
Fresh Healthy Vending International, Inc.
Company Executes Licensing Agreement; Obtains Exclusive Rights to Franchise and Sell the Fro-Yo Kiosks in US and Canada
SAN DIEGO, CA--(NewMediaWire - Feb 11, 2016) - Fresh Healthy Vending International, Inc. (OTCQB: VEND) announced today a definitive agreement with Robofusion, Inc. for an exclusive licensing deal in the United States of America and its territories (excluding Puerto Rico) and Canada. The agreement names Fresh Healthy Vending ("FHV") as the exclusive franchisor to third parties through franchise agreements as well as a seller to purchasers who will self-operate the Reis and Irvy's frozen yogurt vending kiosks.
The innovative Robofusion "Reis and Irvy's" robotic frozen yogurt cube is a one-of-a- kind, unmanned, highly visual "robot" that dispenses frozen yogurt in nine flavors with six possible toppings at a rate of up to 60 servings of frozen yogurt per hour. A 3' x 4' kiosk on wheels, the Reis and Irvy's cube combines mobility with economy of scale, optimizing profit margin per-square-foot and yielding potential long term annuities wherever it's installed. The machines will first be offered to current FHV franchisees beginning March 2016 and new franchisees thereafter.
"Our business model has evolved somewhat in that we are now identifying new concepts that can be franchised using our current infrastructure, concepts that fit in the category of innovation, next generation and if possible, automation. We are extremely happy to have identified the Reis and Irvy's Cube as our next franchise concept offering, as the model requires the same systems and expertise already in place at Fresh Healthy Vending," said FHV Chairman Nick Yates. "We believe that many of the 240 operational franchisees we already cater to are looking for an opportunity to expand their current offerings and utilize the time spent operating their respective franchises for additional profits. This kiosk is a hit for all ages -- combining innovative technology, a high-demand product and interactive experience. It's right up our alley! The technology is patented and the license is exclusive. Overall, we have very high hopes for this deal."
"Robofusion is extremely proud to partner with Fresh Healthy Vending. The Company's established franchisee footprint, exceptional marketing and growth were all very attractive to us," said Allan Jones, CEO of Robofusion. "FHV has demonstrated a real commitment to be the leader in healthy vending and micro-market categories and we look forward to growing together with our frozen yogurt kiosk technology."
The agreement marks Fresh Healthy Vending's first step in adding other franchise opportunities to their portfolio as they anticipate a name-change and a repositioning in the market to expand beyond their Fresh Healthy Vending machines and micro markets in 2016 and beyond.
For more information on Fresh Healthy Vending, new franchise opportunities, the franchise program, or to receive a free healthy vending machine in your school or business, visit www.freshvending.com or call toll free 888-902-7558.
About Fresh Healthy Vending
Fresh Healthy Vending, based in San Diego, California, is North America's leading healthy vending franchisor. Fresh Healthy Vending pioneered the concept of vending machines stocked with tried-and-tested fresh, healthy snack options to serve the growing market of health-conscious consumers. The Company has over 240 active franchisees throughout the United States, Canada, Puerto Rico and the Bahamas, and continually looks to partner with like-minded entrepreneurs who share its vision.
The Company has booked over 2,900 machines for placement in schools, universities, hospitals, community centers, military bases, airports, fitness facilities, YMCAs, libraries and many other locations.
Fresh Healthy Vending's stock is traded on the OTC Markets, Symbol: VEND.
Cautionary note on forward-looking statements
Except for historical information contained in this release, statements in this release may constitute forward-looking statements regarding assumptions, projections, expectations, targets, intentions or beliefs about future events that are based on management's belief, as well as assumptions made by, and information currently available to, management. While the Company believes that expectations are based upon reasonable assumptions, there can be no assurances that goals, results and strategy will be realized. Numerous factors, including risks and uncertainties, terms and availability of financing, may affect actual results and may cause results to differ materially from those expressed in forward-looking statements made by the Company or on its behalf. In addition to statements, which explicitly describe risks and uncertainties, readers are urged to consider statements labeled with such terms as "believes," "belief," "expects," "intends," "feels," "anticipates," "proposes," "proposed," or "plans" to be uncertain and forward-looking. More detailed information on these and additional factors that could affect Fresh Healthy Vending's actual results are described in Fresh Healthy Vending's filings with the Securities and Exchange Commission, including its most recent Form 10-Q for the quarterly period ended September 30, 2015, and its annual report on Form 10-K for the fiscal year ended June 30, 2015. All forward-looking statements in this news release speak only as of the date of this news release and are based on Fresh Healthy Vending's current beliefs and expectations. Fresh Healthy Vending undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.
CONTACT INFORMATION
Contact:
Brenda Manea
714.904.8592
brenda@bamcommunications.biz
$VEND Fresh Healthy Vending Adds Reis and Irvy's Frozen Yogurt Robot to Franchise Portfolio
Source: InvestorsHub NewsWire
SOURCE: Fresh Healthy Vending International, Inc.
Fresh Healthy Vending International, Inc.
Company Executes Licensing Agreement; Obtains Exclusive Rights to Franchise and Sell the Fro-Yo Kiosks in US and Canada
SAN DIEGO, CA--(NewMediaWire - Feb 11, 2016) - Fresh Healthy Vending International, Inc. (OTCQB: VEND) announced today a definitive agreement with Robofusion, Inc. for an exclusive licensing deal in the United States of America and its territories (excluding Puerto Rico) and Canada. The agreement names Fresh Healthy Vending ("FHV") as the exclusive franchisor to third parties through franchise agreements as well as a seller to purchasers who will self-operate the Reis and Irvy's frozen yogurt vending kiosks.
The innovative Robofusion "Reis and Irvy's" robotic frozen yogurt cube is a one-of-a- kind, unmanned, highly visual "robot" that dispenses frozen yogurt in nine flavors with six possible toppings at a rate of up to 60 servings of frozen yogurt per hour. A 3' x 4' kiosk on wheels, the Reis and Irvy's cube combines mobility with economy of scale, optimizing profit margin per-square-foot and yielding potential long term annuities wherever it's installed. The machines will first be offered to current FHV franchisees beginning March 2016 and new franchisees thereafter.
"Our business model has evolved somewhat in that we are now identifying new concepts that can be franchised using our current infrastructure, concepts that fit in the category of innovation, next generation and if possible, automation. We are extremely happy to have identified the Reis and Irvy's Cube as our next franchise concept offering, as the model requires the same systems and expertise already in place at Fresh Healthy Vending," said FHV Chairman Nick Yates. "We believe that many of the 240 operational franchisees we already cater to are looking for an opportunity to expand their current offerings and utilize the time spent operating their respective franchises for additional profits. This kiosk is a hit for all ages -- combining innovative technology, a high-demand product and interactive experience. It's right up our alley! The technology is patented and the license is exclusive. Overall, we have very high hopes for this deal."
"Robofusion is extremely proud to partner with Fresh Healthy Vending. The Company's established franchisee footprint, exceptional marketing and growth were all very attractive to us," said Allan Jones, CEO of Robofusion. "FHV has demonstrated a real commitment to be the leader in healthy vending and micro-market categories and we look forward to growing together with our frozen yogurt kiosk technology."
The agreement marks Fresh Healthy Vending's first step in adding other franchise opportunities to their portfolio as they anticipate a name-change and a repositioning in the market to expand beyond their Fresh Healthy Vending machines and micro markets in 2016 and beyond.
For more information on Fresh Healthy Vending, new franchise opportunities, the franchise program, or to receive a free healthy vending machine in your school or business, visit www.freshvending.com or call toll free 888-902-7558.
About Fresh Healthy Vending
Fresh Healthy Vending, based in San Diego, California, is North America's leading healthy vending franchisor. Fresh Healthy Vending pioneered the concept of vending machines stocked with tried-and-tested fresh, healthy snack options to serve the growing market of health-conscious consumers. The Company has over 240 active franchisees throughout the United States, Canada, Puerto Rico and the Bahamas, and continually looks to partner with like-minded entrepreneurs who share its vision.
The Company has booked over 2,900 machines for placement in schools, universities, hospitals, community centers, military bases, airports, fitness facilities, YMCAs, libraries and many other locations.
Fresh Healthy Vending's stock is traded on the OTC Markets, Symbol: VEND.
Cautionary note on forward-looking statements
Except for historical information contained in this release, statements in this release may constitute forward-looking statements regarding assumptions, projections, expectations, targets, intentions or beliefs about future events that are based on management's belief, as well as assumptions made by, and information currently available to, management. While the Company believes that expectations are based upon reasonable assumptions, there can be no assurances that goals, results and strategy will be realized. Numerous factors, including risks and uncertainties, terms and availability of financing, may affect actual results and may cause results to differ materially from those expressed in forward-looking statements made by the Company or on its behalf. In addition to statements, which explicitly describe risks and uncertainties, readers are urged to consider statements labeled with such terms as "believes," "belief," "expects," "intends," "feels," "anticipates," "proposes," "proposed," or "plans" to be uncertain and forward-looking. More detailed information on these and additional factors that could affect Fresh Healthy Vending's actual results are described in Fresh Healthy Vending's filings with the Securities and Exchange Commission, including its most recent Form 10-Q for the quarterly period ended September 30, 2015, and its annual report on Form 10-K for the fiscal year ended June 30, 2015. All forward-looking statements in this news release speak only as of the date of this news release and are based on Fresh Healthy Vending's current beliefs and expectations. Fresh Healthy Vending undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.
CONTACT INFORMATION
Contact:
Brenda Manea
714.904.8592
brenda@bamcommunications.biz
$ENDV Endonovo Therapeutics Retains Holland & Knight to File for Orphan Drug Designation
Source: InvestorsHub NewsWire
SOURCE: Endonovo Therapeutics, Inc.
Endonovo Therapeutics, Inc.
LOS ANGELES, CA--(NewMediaWire - Feb 11, 2016) - Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), an innovative biotechnology company developing bioelectronics-based products and therapies for regenerative medicine, announced it has retained Holland & Knight to prepare and file the paperwork necessary to obtain an orphan drug designation for Endonovo's proprietary Cytotronics™ product.
Endonovo is requesting the United States Food and Drug Administration (FDA) grant an orphan drug designation to its next-generation, off-the-shelf treatment for Graft-Versus-Host Disease (GVHD) using Cytotronics™ expanded and ex vivo enhanced stem cells from the human umbilical cord.
Orphan drug designation is granted by the FDA to novel drugs and biologics which are defined as those intended for the safe and effective treatment, diagnosis or prevention of rare diseases/disorders that affect fewer than 200,000 people in the U.S. The designation provides incentives for sponsors to develop products for rare diseases, which may include tax credits towards the cost of clinical trials. The orphan drug designation also would entitle Endonovo to a seven-year period of marketing exclusivity in the United States for the Company's orphan indication should Endonovo receive FDA approval for the treatment of GVHD. Therapies with orphan drug status are also not subject to a prescription drug user fee for the orphan indication.
Upon the FDA granting Endonovo an orphan drug designation for the treatment of GVHD, the Company intends to demonstrate the safety and effectiveness of our Cytotronics™ product through adequate and well-controlled studies satisfying the FDA's requirements for Premarket Approval.
Alan Collier, President and CEO, commented, this is the first of many steps for Endonovo receiving FDA approval to market its Cytotronics™ product for the treatment of GVHD. Upon Premarket Approval we will expediently engage new studies to further illustrate our technology's capability in treating a wide-array of other conditions with our biologically potent, off-the-shelf, allogeneic treatment where currently human leukocyte antigen (HLA) markers prevent a recipient from obtaining a matching transplant (graft).
About Graft-Versus-Host Disease (GVHD)
GVHD is a rare complication following allogeneic tissue transplants, including bone marrow and cord blood transplants, wherein immune cells in the transplanted tissue (the graft) recognize the recipient (the host) as "foreign" and begin to attack the host's cells. Acute GVHD can result in significant damage to the liver, skin, mucosa and the gastrointestinal tract and is a major issue associated with high morbidity and mortality in transplants.
About Endonovo Therapeutics
Endonovo Therapeutics, Inc. is an innovative biotechnology company developing bioelectronic devices and therapies for regenerative medicine. Endonovo's Immunotronics™ platform is a non-invasive, non-implantable bioelectronic device for treating/preventing vital organ failure through the reduction of inflammation, cell death and the promotion of regeneration. Endonovo's Cytotronics™ platform provides for a method of expanding and enhancing the biological and therapeutic properties of cells for the development of next-generation cell therapies. The Company's initial concentration is on the treatment of acute and chronic inflammatory conditions of the liver using its proprietary Immunotronics™ platform and the treatment of Graft-Versus-Host Disease using its ex vivo expanded and enhanced stem cells.
Safe Harbor Statement
This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.
Investors: Sign Up for Email Alerts on Endonovo
CONTACT INFORMATION
Investor Relations Contact:
Endonovo Therapeutics, Inc.
Mr. Steven Barnes
Vice President of Investor Relations
(800) 701-1223, Ext. 108
Sbarnes@endonovo.com
www.endonovo.com
$ENDV Endonovo Therapeutics Retains Holland & Knight to File for Orphan Drug Designation
Source: InvestorsHub NewsWire
SOURCE: Endonovo Therapeutics, Inc.
Endonovo Therapeutics, Inc.
LOS ANGELES, CA--(NewMediaWire - Feb 11, 2016) - Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), an innovative biotechnology company developing bioelectronics-based products and therapies for regenerative medicine, announced it has retained Holland & Knight to prepare and file the paperwork necessary to obtain an orphan drug designation for Endonovo's proprietary Cytotronics™ product.
Endonovo is requesting the United States Food and Drug Administration (FDA) grant an orphan drug designation to its next-generation, off-the-shelf treatment for Graft-Versus-Host Disease (GVHD) using Cytotronics™ expanded and ex vivo enhanced stem cells from the human umbilical cord.
Orphan drug designation is granted by the FDA to novel drugs and biologics which are defined as those intended for the safe and effective treatment, diagnosis or prevention of rare diseases/disorders that affect fewer than 200,000 people in the U.S. The designation provides incentives for sponsors to develop products for rare diseases, which may include tax credits towards the cost of clinical trials. The orphan drug designation also would entitle Endonovo to a seven-year period of marketing exclusivity in the United States for the Company's orphan indication should Endonovo receive FDA approval for the treatment of GVHD. Therapies with orphan drug status are also not subject to a prescription drug user fee for the orphan indication.
Upon the FDA granting Endonovo an orphan drug designation for the treatment of GVHD, the Company intends to demonstrate the safety and effectiveness of our Cytotronics™ product through adequate and well-controlled studies satisfying the FDA's requirements for Premarket Approval.
Alan Collier, President and CEO, commented, this is the first of many steps for Endonovo receiving FDA approval to market its Cytotronics™ product for the treatment of GVHD. Upon Premarket Approval we will expediently engage new studies to further illustrate our technology's capability in treating a wide-array of other conditions with our biologically potent, off-the-shelf, allogeneic treatment where currently human leukocyte antigen (HLA) markers prevent a recipient from obtaining a matching transplant (graft).
About Graft-Versus-Host Disease (GVHD)
GVHD is a rare complication following allogeneic tissue transplants, including bone marrow and cord blood transplants, wherein immune cells in the transplanted tissue (the graft) recognize the recipient (the host) as "foreign" and begin to attack the host's cells. Acute GVHD can result in significant damage to the liver, skin, mucosa and the gastrointestinal tract and is a major issue associated with high morbidity and mortality in transplants.
About Endonovo Therapeutics
Endonovo Therapeutics, Inc. is an innovative biotechnology company developing bioelectronic devices and therapies for regenerative medicine. Endonovo's Immunotronics™ platform is a non-invasive, non-implantable bioelectronic device for treating/preventing vital organ failure through the reduction of inflammation, cell death and the promotion of regeneration. Endonovo's Cytotronics™ platform provides for a method of expanding and enhancing the biological and therapeutic properties of cells for the development of next-generation cell therapies. The Company's initial concentration is on the treatment of acute and chronic inflammatory conditions of the liver using its proprietary Immunotronics™ platform and the treatment of Graft-Versus-Host Disease using its ex vivo expanded and enhanced stem cells.
Safe Harbor Statement
This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.
Investors: Sign Up for Email Alerts on Endonovo
CONTACT INFORMATION
Investor Relations Contact:
Endonovo Therapeutics, Inc.
Mr. Steven Barnes
Vice President of Investor Relations
(800) 701-1223, Ext. 108
Sbarnes@endonovo.com
www.endonovo.com
$AMLH Trader's Cheat Sheet
http://www.barchart.com/cheatsheet.php?sym=AMLH
$AMLH Trader's Cheat Sheet
http://www.barchart.com/cheatsheet.php?sym=AMLH
$AMLH Technical Analysis
http://www.stockta.com/cgi-bin/analysis.pl?symb=AMLH&cobrand=&mode=stock
$HCTI is number 22 on BOB
Go $HCTI
$HCTI consolidate is happen and things will be much better for HCTI
Go $HCTI
$HCTI looking good here Mick
Go $HCTI
Nice
Go $HCTI
Agreed but look out for HCTI chart and go from there
Go $HCTI
Agreed
Go $HCTI
Nah...I don't have time for Radio my Friend...
$MJNA Trader's Cheat Sheet
http://www.barchart.com/cheatsheet.php?sym=MJNA